STOCK TITAN
  1. Home
  2. News
  3. BPTS

Biophytis - BPTS STOCK NEWS

Welcome to our dedicated news page for Biophytis (Ticker: BPTS), a resource for investors and traders seeking the latest updates and insights on Biophytis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biophytis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biophytis's position in the market.

News
Biophytis Announces Transfer of ADSs to OTC Market
Rhea-AI Summary
Biophytis, a clinical-stage biotechnology company, announced the transfer of its ADSs to the OTC market after being delisted from Nasdaq due to non-compliance with stockholders' equity requirements. The company's ADSs will now trade on the OTC Pink market under the symbol 'BPTS' while applying to move to the OTCQB market, resulting in significant cost savings. Biophytis remains listed on Euronext Growth Paris.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
Rhea-AI Summary
Biophytis announces a ratio change under its American Depositary Receipt ('ADR') program, transitioning from one ADS representing 100 shares to one ADS representing 4,000 shares. The effective date is April 23, 2024. Existing ADR holders will need to exchange their ADRs for new ones in a one-for-forty ratio, while ADS beneficial holders through intermediaries are not required to take any action. The ADSs will continue to trade on The Nasdaq Capital Market under the symbol 'BPTS'. The Ratio Change is not accompanied by the issuance of new shares, and the Company cautions that the trading price may not necessarily align with the pre-change price multiplied by the new ratio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.01%
Tags
none
-
News
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
Rhea-AI Summary
Biophytis announces the formation of a new Scientific Advisory Board for its phase 2 OBA clinical study in obesity, including renowned experts like Prof. Dennis Villareal and Prof. Francisco Guarner. The company plans to file for an IND with the FDA to start the OBA Phase 2 clinical study in the USA in the coming weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.26%
Tags
management clinical trial
News
Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
Rhea-AI Summary
Biophytis SA announces financial results for 2023 and updates on clinical programs, highlighting progress in COVID-19 treatment and expansion into obesity market. The company plans phase 3 trials, seeks partnerships, and faces financial challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.4%
Tags
earnings
-
News
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Rhea-AI Summary
Biophytis announces the launch of the OBA clinical development program for obesity treatment with promising preclinical results. The program aims to address muscle loss associated with obesity treatment, with BIO101 as a potential solution. The company anticipates significant market growth and positive clinical outcomes by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.4%
Tags
clinical trial
-
News
Results of the Combined General Meeting on April 2, 2024
Rhea-AI Summary
Biophytis SA successfully adopts all resolutions at the General Meeting, including financial delegations, with significant shareholder support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
News
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
Rhea-AI Summary
Biophytis SA presented its phase 3 protocol for RuvembriTM at the International Conference on Frailty and Sarcopenia Research, showcasing promising results from the SARA-INT phase 2 study. The company aims to demonstrate the potential of RuvembriTM in treating sarcopenia, a condition associated with aging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
clinical trial
-
News
Biophytis Announces Receipt of Nasdaq Notice
Rhea-AI Summary
Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) has received a notification from Nasdaq indicating that it no longer satisfies the minimum bid price requirement. The company has a 180-day grace period to regain compliance by maintaining a closing bid price of $1.00 per share or higher for at least ten consecutive business days. Biophytis intends to evaluate its options to achieve compliance within the stipulated period, and its business operations remain unaffected by this notification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil
Rhea-AI Summary
Biophytis SA announces partnership with Innovation Solutions Pharma to accelerate market access for Sarconeos (BIO101) in Brazil. The partnership aims to lift the suspension of the Early Access Program (EAP) authorized in 2022, allowing 80 patients suffering from critical forms of COVID-19 to be treated for 28 days under mechanical ventilation in Brazilian hospitals. The program offers a therapeutic alternative to prevent death in severe COVID-19 cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.99%
Tags
partnership
News
Biophytis Receives Notice of Delisting From Nasdaq and Announces It Will Request a Hearing Before the Nasdaq Hearings Panel
Rhea-AI Summary
Biophytis, a clinical-stage biotechnology company, has received a notice of delisting from Nasdaq due to non-compliance with the minimum stockholders' equity requirement. The company plans to request a hearing before a Nasdaq Hearings Panel to present its plan for regaining compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock BPTS logo
Biophytis

Nasdaq:BPTS

BPTS Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BPTS Stock Data

3.33M
1.11B
0.05%
0.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Paris

About BPTS

biophytis is a biotech company developping therapeutics for aging diseases. it that has been created in 2006 as a spin-off of université pierre et marie curie (paris). biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (bio101, bio103) and dry age-related macular degeneration (bio201).